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Pancreatic neuroendocrine tumors (NETs) are extremely rare, and although insulinomas are the commonest, less than 10% of
insulinomas are malignant. Most patients with insulinomas present with neuroglycopenic symptoms and weight gain attributable
to insulin excess. Here, we report a case where a 67-year-old lady with a background history of type 2 diabetes mellitus and
breakthrough hyperinsulinism who presented with coma. The biochemical proﬁle revealed features typical of insulinoma, and
CT and endosonography conﬁrmed a pancreatic tumor with large volume right-sided liver metastases (biopsy conﬁrming a
neuroendocrine tumor). The patient underwent successful one-step RO surgical resection, distal pancreatectomy, splenectomy,
and right hepatectomy, and 9 months postoperatively, she remains free of recurrent disease. She remains a diabetic.
1.Introduction
Insulinoma is a rare tumour, derived from the beta cells of
the pancreas. The incidence in the general population is 4
cases per million a year [1]. 80% to 90% of insulinomas
are benign, and less than 10% are malignant. Insulinoma is
the most common form of pancreatic NET accounting for
60% of cases [2] and is most commonly seen between the
a g eo f4 0t o6 0y e a r s ,i nf e m a l e s( 6 0 % )[ 1, 3]. They usually
present with symptoms of hyperinsulinism resulting in
neuroglycopenia such as headache, diplopia, blurred vision,
confusion, abnormal behaviour, lethargy, and amnesia.
Rarely, hypoglycemia may result in seizures and coma. Other
features of hyperinsulinism result from the autonomic ner-
vous system including sweating, weakness, hunger, tremor,
nausea, feelings of warmth, anxiety, and palpitations [4].
The symptoms resolve with dextrose infusion and with food
intake. The association of insulinoma in a malignant form
and diabetes mellitus is a rarely reported phenomenon as
presented in the following report. The report also illustrates
how medical management rapidly failed and also how
an aggressive surgical strategy proved to be clinically and
oncologically feasible.
2.CaseReport
A 67-year-old lady was admitted via the emergency depart-
ment after being found unresponsive at home by her
husbandearlyinthemorning.Onpresentation,herGCSwas
9 with normal vital signs. Her glucose level was 8mmol/L,
and the blood gases were normal. On observation an hour
later, her dextrose test was rechecked and fell to 1.5mmol/L
withbloodglucoseof0.9mmol/L.Shewasgivenintravenous
dextrose and her condition improved.
Of note, her past medical history included a two-
year history of type 2 diabetes mellitus, recently diagnosed2 International Journal of Endocrinology
depression, and osteoporosis. Her oral hypoglycemic agents
had been recently withdrawn as her blood sugar levels were
well controlled on dietary changes she had made. Her family
reports that she was increasingly anxious over the last few
months with occasional confused periods. She also had a
4kg weight loss over the last 12 months (10% body weight).
Her daily medications include citalopram, bromazepam,
and weekly bisphosphonate. There was no family history
of diabetes mellitus, hypertension, or hyperparathyroidism.
The patient denied taking any excess medication or oral
hypoglycemic agents.
On examination, the patient was alert but appeared very
anxious; her GCS returned rapidly to normal on intravenous
dextrose. Cardiovascular, gastrointestinal, and neurological
e x a m i n a t i o n sw e r en o r m a la sw e l la sh e ro t h e rl a b o r a t o r y
investigations.
Thepatientunderwenta72-hourfastaspartoftheinves-
tigation but was interrupted at 2 hours due to hypoglycemic
symptoms (sweating, feeling drowsy and unwell). During
this episode, her blood glucose level was conﬁrmed to be low
(1.1mmol/L),Cpeptidewaselevatedat8.2andinsulinlevels
at 91. Her sulfonylurea screen was negative and her other
pancreatic endocrine hormones were sent and came back as
within normal limits.
CT scan of abdomen revealed a 2.6cm by 2.0cm
hypodense mass containing peripheral calciﬁcations in the
body of the pancreas (Figure 1). Multiple low attenuation
liver lesions, with the largest one measuring 5cm, were
seen in segment 8 of the liver. An endoscopic ultrasound
(EUS)alsofounda5-to6-cmoval-shapedhypoechoiclesion
(Figure 1) with irregular margins involving the left body
and junction body/tail of the pancreas clearing invading
the splenic artery with several hypoechoic large local lymph
nodes. EUS-guided biopsies of the pancreatic mass and
nodes were performed. A somatostatin receptor scintigraphy
with octreotide showed intense uptake in the pancreas and
the liver and no distant lesions. Due to the aggressive nature
of the clinical presentation with anorexia and weight loss,
an ultrasound-guided liver biopsy of hepatic metastases was
also performed. Histopathology from all sites conﬁrmed
neuroendocrine diﬀerentiation with diﬀuse chromogranin
A and synaptophysin staining; the Ki-67 proliferation index
varied form <2% in the pancreas to 10 to 15% in liver
metastases (Figure 2).
The initial management consisted of intravenous dex-
trose infusions for multiple episodes of hypoglycemia with
no particular diurnal variations, and these episodes were
not relieved postprandially. Oral diazoxide was rapidly
commenced without any appreciable eﬀect on hypoglycemic
episodes, and the patient was thereafter commenced on
subcutaneous octreotide (100mcg three times a day increas-
ing to 600mcg/day); the latter improved marginally the
glucose levels, but she developed peripheral oedema and
abdominalcramps.Followingamultidisciplinarydiscussion,
it was decided to attempt surgery using either a one-stage
or two-stage strategy. At laparotomy, she underwent a distal
pancreatectomy,splenectomy,andrighthepatectomy.Wedge
excision of segment 2 was also performed at the time of the
procedure. The postoperative period was marked by diﬃcult
tocontrolhyperglycemia,butthepatientmadearapidrecov-
eryandwasﬁttodischargehomeafter14days.Allsymptoms
attributable to hypoglycemia completely disappeared with
the patient experiencing a normal psychological state—no
episodes of anxiety or unexplained confusion or stress as
described prior to presentation. She is in good health with
normal follow-up imaging, C-peptide levels measurement.
She remains diabetic nine months postoperatively, and the
diabetes is diet controlled.
3. Discussion
Insulinomas are insulin-secreting tumours from the beta
cells of the pancreas. 80% of patients diagnosed with
insulinomas have single, usually small (60%–75% are less
than(<)1.5cm),benign (TNM Stage1or stageIIa) tumours
[5]. Only 10% have malignant tumours and the remaining
10% have multiple benign lesions [6, 7]. Approximately 40%
of the tumours are <1cm in diameter and can be as small
as 2mm and diﬃcult to detect [7]. Malignant tumours tend
to be larger and >3cm in diameter as was the case here [7].
The clinical and biochemical pattern as depicted by this case
reportﬁtwiththeclassicalpatternsdescribedintheliterature
[8].
Additionally, the imaging features here did not pose
any particular diﬃculties with typical features on CT and
endosonography. Somatostatin receptor scintigraphy is often
negative in the detection of small benign tumours (40
to 50%) [8]. In malignant disease, positive scintigraphy
is described due to a diﬀerent relative distribution of
somatostatin receptor subtypes and a higher rate of scan-
positivity with this technique can be expected [9–11], and
this can be useful in planning management.
Insulinomas occurring in diabetics is very rare, and there
areveryfewpublishedreportsintheliterature.Between1927
and 1992, there was only one case of insulinoma occurring
in a diabetic patient, out of the 313 conﬁrmed cases of
insulinomas in Mayo Clinic series [12,13]. In Japan, a review
of 443 cases of insulinomas between 1976 and 1990 revealed
only one patient who had coexisting diabetes [12, 14]. In
one institution in Taiwan, out of 23 cases of insulinomas
seen between July 1984 and March 2006, only one case of
coexisting diabetes was recorded [12].
The management of insulinoma depends on tumour
localisation, the malignant potential, and presence of metas-
tasis. Medical treatment for insulinomas is indicated for
diﬃcult to control hypoglycemia symptoms usually while
awaiting more deﬁnite therapeutic strategies. Diazoxide (50–
300mg/day which can be increased up to 600mg/Day),
whichinhibitsinsulinsecretionfromthepancreaticbetacells
and stimulates gluconeogenesis, has been used successfully
to some extent for symptom control while awaiting more
deﬁnitive management [15]. The main side eﬀects include
palpitations, oedema, and hirsutism and they occurred in
47% of patients on diazoxide [16]. A thiazide diuretic
is usually used both to reduce oedema and provide a
hyperglycemic eﬀect [16]. Diazoxide is particularly helpful
and used in patients with tumour nonlocalisation, failed
surgery, metastatic disease, and patients unﬁt for surgeryInternational Journal of Endocrinology 3
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Figure 1: MD-CT scan demonstrating a hypodense lesion (arrow) with spots of peripheral calciﬁcations in the body/tail of pancreas as
wells as a large hypodense liver metastasis in the right lobe of liver, arrow (b). (c, d) show at endoscopic ultrasound the presence of the
heterogeneous hypoechoic mass involving the body and tail of pancreas with numerous hypoechoic well deﬁned peri-pancreatic lymph
nodes (d).
[16]. The beneﬁcial eﬀects are often however short-lived.
Somatostatin analogues can also be employed due to their
inhibitory eﬀects on glucagon and growth hormone secre-
tion and lowers endogenous insulin production. The main
mechanism of action of somatostatin analogues in insuli-
noma is the inhibition of insulin secretion by beta cells of the
pancreas. This is achieved by binding to somatostatin (SRIF)
receptors mainly sst2 and sst5 which are expressed by beta
cells [11]. Traditional systemic cytotoxic combinations have
been disappointing in managing patients with metastatic
disease [17]. Recently, case reports on both the control of
hypoglycemia and even objective response have been repor-
ted in patients with metastatic disease using an mTOR
(mammalian target of rapamycin) inhibitor—everolimus
[18, 19]. More data are required to substantiate these
interesting ﬁndings.
Surgery is the recommended treatment in most cases of
insulinomas with limited resection recommended for single
small lesions [8]. Management of malignant insulinomas
should include an oncological resection where possible and
attempts at RO (complete resection with no microscopic
residual tumour) resection including resection of liver
metastases [20]. We decided to embark on either a one-
or two-stage resection in this case; planned oncological
resection of the diseased pancreas and nodes and if the
liver metastases were not resectable at that time, portal
embolisation to the right followed by right hepatectomy at
a later date was planned as described [21]. Fortunately, a
one-stage strategy was possible here with a rapid recovery;
to the extent that postoperative hyperglycemia was diﬃcult
to control. The median disease-free survival after curative
resection is 5 years, but recurrence occurs in more than
60% at a median interval of 2.5–3 years. Median survival
with recurrent tumours is less than 2 years [22]. Palliative
resection may prolong median survival [8]. If an RO
resection is not deemed possible, then debulking procedures
can be considered to aid symptomatic control. Other strate-
gies include: radiofrequency ablation [23], and transarterial
chemoembolisation [23] or peptide receptor radionuclide
therapy [24]. Based on all previous literature, the better
survival rates were associated with resection of primary
tumour and intention to treat metastatic disease [25].4 International Journal of Endocrinology
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Figure 2: US-guided liver biopsy staining H & E (a) demonstrating a rather uniform population of sheets of small cells arranged in
manner (×40 in (b)). Immunohistochemistry with a Ki-67 marker (Mib-1) (c) estimated here to be 15% and positive immunostaining
with chromogranin A (d).
4. Conclusion
Metastatic insulinoma in a diabetic patient is an extremely
rare disease. Hypoglycemia in a diabetic patient following
w i t h d r a w a lo fo r a lh y p o g l y c e m i ca g e n t sw i t ha s s o c i a t e d
improvement in diabetes status should be investigated for
insulinoma. Surgical resection should always be consid-
ered where possible for insulinomas whether malignant or
not.
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